Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487058 | 0.94 | HSPD1 (0.44) | MAPTHSPD1HSPE1CYSLTR2CYSLTR1 | |
| SCHEMBL6477587 | 0.92 | HSPD1 (0.43) | MAPTHSPD1HSPE1 | |
| SCHEMBL9721974 | 0.86 | KDR (0.58) | KDRMAPTCYSLTR2CYSLTR1FFAR1 | |
| SCHEMBL6486402 | 0.82 | CYSLTR2 (0.48) | HSPD1HSPE1CYSLTR2CYSLTR1FFAR1 | |
| SCHEMBL6477222 | 0.79 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1 | |
| SCHEMBL6486507 | 0.78 | MCL1 (0.45) | CYSLTR2CYSLTR1 | |
| SCHEMBL9721949 | 0.78 | MAPT (0.58) | KDRMAPTCYSLTR2CYSLTR1 | |
| SCHEMBL6476503 | 0.76 | CYSLTR2 (0.48) | MAPTCYSLTR2CYSLTR1 | |
| SCHEMBL6482915 | 0.76 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1 | |
| SCHEMBL7737836 | 0.76 | PPARG (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | KDR 3973/4885MAPT 4257/4885HSPD1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.